Paeoniflorin could activate PI3K/Akt signaling pathway to protect the PC12 cell injury induced by Aβ25-35.Paeoniflorin most likely contributes to the therapy for liver disease by exerting anti-inflammatory effects on HHSECs through blocking IL-8 secretion via downregulation of ERK1/2 and Akt.PF alleviates psoriatic skin lesions by inhibiting inflammation, which provides new insights into the immunomodulatory effect of PF in psoriasis treatment.Paeoniflorin pretreatment protects mice against Con A-induced liver injury via inhibition of several inflammatory mediators and, at least in part, by suppressing CD4(+), CD8(+) and NKT cell infiltration in liver. The beneficial effect of paeoniflorin may be related to the downregulation of TLR4 expression and the inhibition of NF-κB activation.Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1α expression partly through mTOR pathway and paeoniflorin may be a potential therapeutic agent for liver fibrosis.
Cell Experiment | |
---|---|
Cell lines | PC12 cells |
Preparation method | Cell Viability Assessment Cell viability was measured using a quantitative colori-metric assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-nyl tetrazolium bromide (MTT) (Sigma-Aldrich, USA) as reported previously (Mosmann 1983). Briefly, cells were seeded into collagen I-coated 96-well plates at a density of 1*104 per well. At the completion of the 24-h treatment, 10 μL MTT solution (5 mg/mL) was added. Following incubation for 4 h at 37 ℃, 100 μL dimethyl sulfoxide (DMSO) was used to dissolve crystals. The absorbance was measured using a microplate reader (Bio-Rad, USA) and cell viability was expressed as a percentage of control value. |
Concentrations | 0, 25, 50, 100, 200 and 400 μM |
Incubation time | 24 h |
Animal Experiment | |
---|---|
Animal models | Adult male Sprague-Dawley rats |
Formulation | PBS, pH 7.5, 0.1 M at a concentration of 200 μg/μL |
Dosages | 15 mg/kg and 30 mg/kg for 20 consecutive days |
Administration | i.p. |
Molecular Weight | 480.46 |
Formula | C23H28O11 |
CAS Number | 23180-57-6 |
Form | Solid |
Solubility (25°C) | Water > 80 mg/mL DMSO > 60 mg/mL |
Storage | -20°C, dry, sealed |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related HIF Products |
---|
3-Aminobenzoic acid
3-Aminobenzoic acid is a hypoxia-inducible factor-1α (HIF-1α) inhibitor. |
Steppogenin
Steppogenin is a potent inhibitor of HIF-1α and DLL4, with IC50 values of 0.56 and 8.46 μM, respectively. |
HIV-IN-7
Axl-IN-16 is a Axl inhibitor. |
HIF-2α-IN-9
HIF-2α-IN-9 is an inhibitor ofHIF-2α. |
PHD-IN-2
PHD-IN-2 is a PHD antagonist (IC50: < 5 nM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.